yvandenbroek
/
sprookjes
/
Login
Register
TriplyDB
sprookjes
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
2
Q47445525-D08D1F43-4164-4163-BA2B-AC90AD796171
Q47445525-D08D1F43-4164-4163-BA2B-AC90AD796171
BestRank
Statement
http://www.wikidata.org/entity/statement/Q47445525-D08D1F43-4164-4163-BA2B-AC90AD796171
Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy.
P2860
Q47445525-D08D1F43-4164-4163-BA2B-AC90AD796171
BestRank
Statement
http://www.wikidata.org/entity/statement/Q47445525-D08D1F43-4164-4163-BA2B-AC90AD796171
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
0778da498807aa06bb50b0e3055331cb0460011b
P2860
Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells.